Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3/4, Prospective, Multinational, Open-label, Noninferiority Study of Alglucosidase Alfa Manufactured at the 160 L and 4000 L Scales in Treatment Naïve Patients With Infantile-Onset Pompe Disease

NCT01597596 is registered in ClinicalTrials.gov with Genzyme, a Sanofi Company as lead sponsor.

NCT NCT01597596
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01597596 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3/4, Prospective, Multinational, Open-label, Noninferiority Study of Alglucosidase Alfa Manufactured at the 160 L and 4000 L Scales in Treatment Naïve Patients With Infantile-Onset Pompe Disease
Lead sponsor
Genzyme, a Sanofi Company
Phase
Phase 4
Overall status
Terminated
Start date
August 31, 2012
Completion date
December 31, 2014
Enrollment
4 (actual)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

acid maltase deficiency, glycogen storage disease type ii (gsd ii), glycogenosis 2, pompe disease (infantile-onset)